Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227605 | 0.89 | IDH1 (0.31) | IDH1 | |
| SCHEMBL5227610 | 0.89 | IDH1 (0.31) | IDH1 | |
| SCHEMBL6293531 | 0.85 | — | — | |
| SCHEMBL2822020 | 0.85 | IDH1 (0.31) | IDH1PTGDR2 | |
| SCHEMBL2822017 | 0.85 | IDH1 (0.31) | IDH1PTGDR2 | |
| SCHEMBL2818413 | 0.85 | IDH1 (0.31) | IDH1PTGDR2 | |
| SCHEMBL2818416 | 0.85 | IDH1 (0.31) | IDH1PTGDR2 | |
| SCHEMBL5672726 | 0.84 | HDAC1 (0.34) | IDH1PTGDR2 | |
| SCHEMBL5229789 | 0.83 | IDH1 (0.34) | IDH1PTGDR2 | |
| SCHEMBL5229785 | 0.83 | IDH1 (0.34) | IDH1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150980-B1 | 16-HALOGEN-EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-20050187270-A1 | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-25 | — | — | US | disclosed |
| US-6610736-B1 | Antitumor | SCHERING AG (DE) | 2003-08-26 | — | — | US | disclosed |
| EP-1150980-A2 | 16-HALOGEN-EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000049021-A2 | 16-HALOGEN-EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187270-A1 | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use | ABCB1, UGT2B17, CYP7B1 | IDH1 2355/4885PTGDR2 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.